Published in BMC Cardiovasc Disord on January 06, 2017
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet (2007) 6.77
Drug-eluting coronary-artery stents. N Engl J Med (2013) 3.69
Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis. Results from a prospective multicenter study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]). JACC Cardiovasc Interv (2012) 2.24
In-stent neoatherosclerosis: a final common pathway of late stent failure. J Am Coll Cardiol (2012) 2.09
Current treatment of in-stent restenosis. J Am Coll Cardiol (2014) 2.05
A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) trial. J Am Coll Cardiol (2006) 1.72
Impact of coronary lesion complexity on drug-eluting stent outcomes in patients with and without diabetes mellitus: analysis from 18 pooled randomized trials. J Am Coll Cardiol (2014) 1.61
Long-term outcomes after the percutaneous treatment of drug-eluting stent restenosis. JACC Cardiovasc Interv (2011) 1.59
Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol (2010) 1.51
Long-term clinical and angiographic outcomes of diabetic patients after revascularization with early generation drug-eluting stents. Am Heart J (2012) 1.47
Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J (2015) 1.15
Comparison of three-year clinical outcomes after sirolimus-eluting stent implantation among insulin-treated diabetic, non-insulin-treated diabetic, and non-diabetic patients from j-Cypher registry. Am J Cardiol (2011) 0.99
Treatment of drug-eluting stent restenosis the new pilgrimage: quo vadis? J Am Coll Cardiol (2010) 0.97
Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era. Am Heart J (2007) 0.94
Early (before 6 months), late (6-12 months) and very late (after 12 months) angiographic scaffold restenosis in the ABSORB Cohort B trial. EuroIntervention (2015) 0.86
Comparison of 2-year outcomes of repeated second-generation drug-eluting stent implantation for focal-type versus nonfocal-type in-stent restenosis. Coron Artery Dis (2015) 0.82
Association between tissue characteristics assessed with optical coherence tomography and mid-term results after percutaneous coronary intervention for in-stent restenosis lesions: a comparison between balloon angioplasty, paclitaxel-coated balloon dilatation, and drug-eluting stent implantation. Eur Heart J Cardiovasc Imaging (2015) 0.81
New roads, new ruts: lessons from drug-eluting stent restenosis. JACC Cardiovasc Interv (2011) 0.80
Treatment of coronary in-stent restenosis with bioabsorbable vascular scaffolds. J Am Coll Cardiol (2014) 0.80
The impact of diabetes mellitus on long-term clinical outcomes after percutaneous coronary saphenous vein graft interventions in the drug-eluting stent era. J Interv Cardiol (2014) 0.80
Influence of diabetes mellitus on long-term outcomes of patients with unprotected left main coronary artery disease treated with either drug-eluting stents or coronary artery bypass grafting. Int Heart J (2014) 0.78
In-stent neointimal characteristics and late neointimal response after drug-eluting stent implantation: A preliminary observation. J Cardiol (2015) 0.78
Long-term outcomes of drug-eluting stent therapy for in-stent restenosis versus de novo lesions. J Interv Cardiol (2013) 0.77